Candel Therapeutics (CADL) announced the appointment of Maha Radhakrishnan, M.D., to the Company’s Board of Directors effective June 4, 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics’ CAN-2409: Promising Phase 3 Results and Buy Rating for Prostate Cancer Treatment
- Buy Recommendation for Candel Therapeutics: Promising Data on CAN-2409 Treatment for Prostate Cancer
- Candel Therapeutics to hold a conference call
- Candel Therapeutics Receives FDA RMAT Designation for CAN-2409
- Candel Therapeutics receives FDA RMAT designation to CAN-2409